Effect of steviol glycosides on human health with emphasis on type 2 diabetic biomarkers: A systematic review and meta-analysis of randomized controlled trials

Nutrients

Volumn 11, Issue 9, 2019, Pages

  Anker, Camilla Christine Bundgaard ^a   Rafiq, Shamaila ^a   Jeppesen, Per Bendix ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Blood pressure; Bmi; Fasting blood glucose; HbA1c; Lipids; Steviol glycosides; Type 2 diabetes

Indexed keywords

AGLYCONE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CHOLESTEROL; FATTY ACID; GLUCAGON; GLYCOSIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOSACCHARIDE; PLACEBO; STEVIOL; STEVIOSIDE; SWEETENING AGENT; TRIACYLGLYCEROL; GLUCOSIDE; KAURANE DERIVATIVE;

ANTIDIABETIC ACTIVITY; BODY MASS; BODY WEIGHT CONTROL; CALORIC INTAKE; CARDIOVASCULAR RISK; CHEMICAL STRUCTURE; DIASTOLIC BLOOD PRESSURE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HUMAN; HYPERTENSION; HYPOLIPIDEMIC ACTIVITY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; LIFESTYLE; META ANALYSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STEVIA REBAUDIANA; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD; CHEMISTRY; DRUG EFFECT;

BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DITERPENES, KAURANE; ENERGY INTAKE; GLUCOSIDES; HUMANS; INSULIN;

EID: 85071439957     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu11091965     Document Type: Review

References (72)

1. Chatterjee, S.; Khunti, K.; Davies, M.J. Type 2 diabetes. Lancet 2017, 389, 2239-2251.
2. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87, 4-14.
3. IDF Diabetes Atlas-8th Edition. International Diabetes Federation. 2017. Available online:http://www.diabetesatlas.org/across-the-globe.html (accessed on 9 October 2018).
4. Kussmann, M.; Morine, M.J.; Hager, J.; Sonderegger, B.; Kaput, J. Perspective: A systems approach to diabetes research. Front. Genet. 2013, 4, 1-11.
5. Donath, M.Y.; Shoelson, S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11, 98-107.
6. Henry, R.R. Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes. Clin. Ther. 2003, 25 (Suppl. 2), B47-B63.
7. Lebovitz, H.E. Type 2 Diabetes: An Overview. Clin. Chem. 1999, 45, 1339-1345.
8. Weir, G.C.; Bonner-Weir, S. Five of stages of evolving β-cell dysfunction during progression to diabetes. Diabetes 2004, 53 (Suppl. 3), S16-S21.
9. Khavandi, K.; Amer, H.; Ibrahim, B.; Brownrigg, J. Strategies for preventing type 2 diabetes: An update for clinicians. Ther. Adv. Chronic Dis. 2013, 4, 242-261.
10. Eddouks, M.; Bidi, A.; El Bouhali, B.; Hajji, L.; Zeggwagh, N.A. Antidiabetic plants improving insulin sensitivity. J. Pharm. Pharmacol. 2014, 66, 1197-1214.
11. Chan, C.-H.; Ngoh, G.-C.; Yusoff, R. A brief review on anti diabetic plants: Global distribution, active ingredients, extraction techniques and acting mechanisms. Pharmacogn. Rev. 2012, 6, 22-28.
12. Patel, D.K.; Prasad, S.K.; Kumar, R.; Hemalatha, S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac. J. Trop. Biomed. 2012, 2, 320-330.
13. Casanova, L.M.; Gu, W.; Jeppesen, P.B. Phenolic Substances from Ocimum Species Enhance Glucose-Stimulated Insulin Secretion and Modulate the Expression of Key Insulin Regulatory Genes in Mice Pancreatic Islets. J. Nat. Prod. 2017, 80, 3267-3275.
14. Anton, S.D.; Martin, C.K.; Han, H.; Coulon, S.; Cefalu, W.T.; Geiselman, P.; Williamson, D.A. Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. Appetite 2010, 55, 37-43.
15. Barriocanal, L.A.; Palacios, M.; Benitez, G.; Benitez, S.; Jimenez, J.T.; Jimenez, N.; Rojas, V. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics. Regul. Toxicol. Pharmacol. 2008, 51, 37-41.
16. Chan, P.; Tomlinson, B.; Chen, Y.; Liu, J.; Hsieh, M.; Cheng, J. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. Br. J. Clin. Pharmacol. 2000, 50, 215-220.
17. da Silva, G.E.C.; Assef, A.H.; Albino, C.C.; Ferri, L.d.F.; Tasin, G.; Takahashi, M.H.; Filho, W.E.; Bazotte, R.B. Investigation of the Tolerability of Oral Stevioside in Brazilian Hyperlipidemic Patients. Brazilian Arch. Biol. Technol. 2006, 49, 583-587.
18. Gregersen, S.; Jeppesen, P.B.; Holst, J.J.; Hermansen, K. Antihyperglycemic Effects of Stevioside in Type 2 Diabetic Subjects. Metabolism 2004, 53, 73-76.
19. Hsieh, M.; Chan, P.; Sue, Y.; Liu, J.; Liang, T.H.; Huang, T.; Tomlinson, B.; Sing, M.; Chow, S.; Kao, P.; et al. Efficacy and Tolerability of Oral Stevioside in Patients with Mild Essential Hypertension: A Two-Year, Randomized, Placebo-Controlled Study. Clin. Ther. 2003, 25, 2797-2808.
20. Geuns, J.M.C.; Buyse, J.; Vankeirsbilck, A.; Temme, E.H.M. Metabolism of Stevioside by Healthy Subjects. Exp. Biol. Med. 2007, 232, 164-173.
21. Maki, K.C.; Curry, L.L.; Carakostas, M.C.; Tarka, S.M.; Reeves, M.S.; Farmer, M.V.; Mckenney, J.M.; Toth, P.D.; Schwartz, S.L.; Lubin, B.C.; et al. The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure. Food Chem. Toxicol. 2008, 46, 40-46.
22. Maki, K.C.; Curry, L.L.; Reeves, M.S.; Toth, P.D.; Mckenney, J.M.; Farmer, M.V.; Schwartz, S.L.; Lubin, B.C.; Boileau, A.C.; Dicklin, M.R.; et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food Chem. Toxicol. 2008, 46, S47-S53.
23. Maki, K.C.; Curry, L.L.; McKenney, J.M.; Farmer, M.V.; Reeves, M.S.; Dicklin, M.R.; Gerich, J.E.; Zinman, B. Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus. FASEB J. 2009, 23, abstr 351.6.
24. Onakpoya, J.; Heneghan, C.J. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials. Eur. J. Prev. Cardiol. 2015, 22, 1575-1587.
25. Tey, S.L.; Salleh, N.B.; Henry, J.; Forde, C.G. Effects of aspartame-, monk fruit-, stevia- and sucrosesweetened beverages on postprandial glucose, insulin and energy intake. Int. J. Obes. 2017, 41, 450-457.
26. Jeppesen, P.B.; Gregersen, S.; Alstrup, K.K.; Hermansen, K. Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: Studies in the diabetic Goto-Kakizaki (GK) rats. Phytomedicine 2002, 9, 9-14.
27. Jeppesen, P.B.; Gregersen, S.; Poulsen, C.R.; Hermansen, K. Stevioside acts directly on pancreatic β cells to secrete insulin: Actions independent of cyclic adenosine monophosphate and adenosine triphosphatesensitivie K+-channel activity. Metabolism 2000, 49, 208-214.
28. Philippaert, K.; Pironet, A.; Mesuere, M.; Sones, W.; Vermeiren, L.; Segal, A.; Antoine, N.; Gysemans, C.; Laureys, J.; Kerselaers, S.; et al. Steviol glycosides enhance pancreatic beta-cell function and taste sensation by potentiation of TRPM5 channel activity. Nat. Commun. 2017, 8, 14733.
29. Chen, T.H.; Chen, S.C.; Chan, P.; Chu, Y.L.; Yang, H.Y.; Cheng, J.T. Mechanism of the Hypoglycemic Effect of Stevioside, a Glycoside of Stevia rebaudiana. Planta Med. 2005, 71, 108-113.
30. Nordentoft, I.; Jeppesen, P.B.; Hong, J.; Abudula, R.; Hermansen, K. Isosteviol increases insulin sensitivity and changes gene expression of key insulin regulatory genes and transcription factors in islets of the diabetic KKAy mouse. Diabetes Obes. Metab. 2008, 10, 939-949.
31. Chang, J.-C.; Wu, M.C.; Liu, I.-M.; Cheng, J.-T. Increase of Insulin Sensitivity by Stevioside in Fructose-rich Chow-fed Rats. Horm. Metab. Res. 2005, 37, 610-616.
32. Jeppesen, P.B.; Gregersen, S.; Rolfsen, S.E.D.; Jepsen, M.; Colombo, M.; Agger, A.; Xiao, J.; Kruhøffer, M.; Ørntoft, T.; Hermansen, K. Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat. Metabolism 2003, 52, 372-378.
33. Brahmachari, G.; Mandal, L.C.; Roy, R.; Mondal, S.; Brahmachari, A.K. Stevioside and related compounds-Molecules of pharmaceutical promise: A critical overview. Arch. Pharm. (Weinheim) 2011, 344, 5-19.
34. Brandle, J.E.; Starratt, A.N.; Gijzen, M. Stevia rebaudiana: Its agricultural, biological, and chemical properties. Can. J. Plant Sci. 1998, 78, 527-536.
35. Carakostas, M.C.; Curry, L.L.; Boileau, A.C.; Brusick, D.J. Overview: The history, technical function and safety of rebaudioside A, a naturally occurring steviol glycoside, for use in food and beverages. Food Chem. Toxicol. 2008, 46, 1-10.
36. Samuel, P.; Ayoob, K.T.; Magnuson, B.A.; Wölwer-rieck, U.; Jeppesen, P.B.; Rogers, P.J.; Rowland, I.; Mathews, R. Stevia Leaf to Stevia Sweetener: Exploring Its Science, Benefits, and Future Potential. J. Nutr. 2018, 148, 1186S-1205S.
37. Purkayastha, S.; Markosyan, A.; Prakash, I.; Bhusari, S.; Pugh, G.; Lynch, B.; Roberts, A. Steviol glycosides in purified stevia leaf extract sharing the same metabolic fate. Regul. Toxicol. Pharmacol. 2016, 77, 125-133.
38. Magnuson, B.A.; Carakostas, M.C.; Moore, N.H.; Poulos, S.P.; Renwick, A.G. Biological fate of low-calorie sweeteners. Nutr. Rev. 2016, 74, 670-689.
39. Hutapea, M.; Toskulkao, C.; Buddhasukh, D.; Wilairat, P.; Glinsukon, T. Digestion of Stevioside, a Natural Sweetener, by Various Digestive Enzymes. J. Clin. Biochem. Nutr. 1997, 23, 177-186.
40. Anchi, R.A.Z.; Ietta, P.I.P. Metabolism of Stevioside and Rebaudioside A from Stevia rebaudiana Extracts by Human Microflora. J. Agric. Food Chem. 2003, 51, 6618-6622.
41. Curi, R.; Alvarez, M.; Bazotte, R.B.; Botion, L.M.; Godoy, J.L.; Bracht, A. Effect of Stevia rebaudiana on glucose tolerance in normal adult humans. Brazilian J. Med. Biol. Res. 1986, 19, 771-774.
42. Geuns, J.M.C.; Augustijns, P.; Mols, R.; Buyse, J.G.; Driessen, B. Metabolism of stevioside in pigs and intestinal absorption characteristics of stevioside, rebaudioside A and steviol. Food Chem. Toxicol. 2003, 41, 1599-1607.
43. Jeppesen, P.; Barriocanal, L.; Meyer, M.; Palacios, M.; Canete, F.; Benitez, S.; Logwin, S.; Schupmann, Y.; Benitez, G.; Jimenez, J. Efficacy and tolerability of oral stevioside in patients with type 2 diabetes: A longterm, randomized, double-blinded, placebo-controlled study. Diabetologia 2006, 49 (Suppl. 1), 511-512.
44. Ritu, M.; Nandini, J. Nutritional composition of Stevia rebaudiana, a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. J. Sci. Food Agric. 2016, 96, 4231-4234.
45. Chan, P.; Xu, D.-Y.; Liu, J.-C.; Chen, Y.-J.; Tomlinson, B.; Huang, W.-P.; Cheng, J.-T. The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats. Life Sci. 1998, 63, 1679-1684.
46. Melis, M.S.; Sainati, A.R. Effect of calcium and verapamil on renal function of rats during treatment with stevioside. J. Ethnopharmacol. 1991, 33, 257-262.
47. Koyama, E.; Sakai, N.; Ohori, Y.; Kitazawa, K. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol, in rats and humans. Food Chem. Toxicol. 2003, 41, 875-883.
48. Gardner, C.; Wylie-Rosett, J.; Gidding, S.S.; Steffen, F.L.M.; Johnson, F.R.K.; Reader, D.; Lichtenstein, A.H. Nonnutritive sweeteners: Current use and health perspectives - A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2012, 35, 1798-1808.
49. Lailerd, N.; Saengsirisuwan, V.; Sloniger, J.A.; Toskulkao, C.; Henriksen, E.J. Effects of stevioside on glucose transport activity in insulin-sensitive and insulin-resistant rat skeletal muscle. Metabolism 2004, 53, 101-107.
50. Bracht, K.; Alvarez, M.; Bracht, A. Effects of Stevia rebaudiana natural products on rat liver mitochondria. Biochem. Pharmacol. 1985, 34, 873-882.
51. Marabita, F.; Islam, M.S. Expression of transient receptor potential channels in the purified human pancreatic β-cells. Pancreas 2017, 46, 97-101.
52. Lee, C.N.; Wong, K.L.; Liu, J.C.; Chen, Y.J.; Cheng, J.T.; Chan, P. Inhibitory effect of stevioside on calcium influx to produce antihypertension. Planta Med. 2001, 67, 796-799.
53. Criteria for Judging Risk of Bias. Available online: https://handbook-5-1.cochrane.org/chapterff8/tableff8_5_d_criteriaffforffjudging_riskffof_bias_in_theffriskffof.htm (accessed on 11 November 2018).
54. Rugge, B.; Balshem, H.; Sehgal, R.; Relevo, R.; Gorman, P.; Helfand, M. Appendix A Lipid Conversion Factors. Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism; Agency for Healthcare Research and Quality (US): Rockville, MD, USA; 2011.
55. Review Manager (RevMan) (Computer Program); Version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, Denmark, 2011.
56. Al-Dujaili, E.A.S.; Twaij, H.; Bataineh, Y.A.; Arshad, U.; Amjid, F.; Al-Dujaili, E.A.S.; Twaij, H.; Bataineh, Y.A.; Arshad, U.; Amjid, F. Effect of Stevia Consumption on Blood Pressure, Stress Hormone Levels and Anthropometrical Parameters in Healthy Persons. Am. J. Pharmacol. Toxicol. 2017, 12, 7-17.
57. Rizwan, F.; Rashid, H.U.; Yesmine, S.; Monjur, F.; Chatterjee, T.K. Preliminary analysis of the effect of Stevia (Stevia rebaudiana) in patients with chronic kidney disease (stage I to stage III). Contemp. Clin. Trials Commun. 2018, 12, 17-25.
58. Shin, D.H.; Lee, J.H.; Kang, M.S.; Kim, T.H.; Jeong, S.J.; Kim, C.H.; Kim, S.S.; Kim, I.J. Glycemic effects of rebaudioside a and erythritol in people with glucose intolerance. Diabetes Metab. J. 2016, 40, 283-289.
59. Ulbricht, C.; Isaac, R.; Milkin, T.; Poole, E.A.; Rusie, E.; Serrano, J.M.G.; Weissner, W.; Windsor, R.C.; Woods, J. An evidence-based systematic review of stevia by the Natural Standard Research Collaboration. Cardiovasc. Hematol. Agents Med. Chem. 2010, 8, 113-127.
60. Ferri, L.; Alves-Do-Prado, W.; Yamada, S.S.; Gazola, S.; Batista, M.R.; Bazotte, R.B. Investigation of the Antihypertensive Effect of Oral Crude Stevioside in Patients with Mild Essential Hypertension. Phyther. Res. 2006, 20, 732-736.
61. Gupta, E.; Purwar, S.; Sundaram, S.; Rai, G.K. Nutritional and therapeutic values of Stevia rebaudiana: A review. J. Med. Plants Res. 2013, 7, 3344-3353.
62. Thomas, J.E.; Glade, M.J. Stevia: It’s Not Just About Calories. Open Obes. J. 2010, 2, 101-109.
63. Buse, J.B.; Tan, M.H.; Prince, M.J.; Erickson, P.P. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes. Obes. Metab. 2004, 6, 133-156.
64. Jeppesen, P.B.; Rolfsen, S.E.D.; Agger, A.; Gregersen, S.; Colombo, M.; Xiao, J.; Hermansen, K. Can Stevioside in Combination with a Soy-Based Dietary Supplement Be a New Useful Treatment of Type 2 Diabetes?-An in vivo Study in the Diabetic Goto-Kakizaki Rat. Rev. Diabet. Stud. 2006, 3, 189-189.
65. Park, J.E.; Cha, Y.S. Stevia rebaudiana Bertoni extract supplementation improves lipid and carnitine profiles in C57BL/6J mice fed a high-fat diet. J. Sci. Food Agric. 2010, 90, 1099-1105.
66. Sharma, N.; Mogra, R.; Upadhyay, B. Effect of Stevia Extract Intervention on Lipid Profile. Stud. Ethno-Med. 2009, 3, 137-140.
67. Atteh, J.O.; Onagbesan, O.M.; Tona, K.; Decuypere, E.; Geuns, J.M.C.; Buyse, J. Evaluation of supplementary stevia (Stevia rebaudiana, bertoni) leaves and stevioside in broiler diets: Effects on feed intake, nutrient metabolism, blood parameters and growth performance. J. Anim. Physiol. Anim. Nutr. 2008, 92, 640-649.
68. King, D.E.; Mainous, A.G.; Matheson, E.M.; Everett, C.J. Impact of healthy lifestyle on mortality in people with normal blood pressure, LDL cholesterol, and C-reactive protein. Eur. J. Prev. Cardiol. 2013, 20, 73-79.
69. Gibbs, B.B.; Brancati, F.L.; Chen, H.; Coday, M.; Jakicic, J.M.; Lewis, C.E.; Stewart, K.J.; Clark, J.M. Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. Eur. J. Prev. Cardiol. 2014, 21, 608-617.
70. Rawshani, A.; Rawshani, A.; Franzén, S.; Eliasson, B.; Svensson, A.-M.; Miftaraj, M.; McGuire, D.K.; Sattar, N.; Rosengren, A.; Gudbjörnsdottir, S. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N. Engl. J. Med. 2017, 376, 1407-1418.
71. Imputing Standard Deviations for Changes from Baseline. Available online: https://handbook-5-1.cochrane.org/chapterff16/16_1_3_2_imputing_standard_deviations_forffchanges_from_baseline.htm (accessed on 11 November 2018).
72. Golomb, B.A.; Erickson, L.C.; Koperski, S.; Sack, D.; Enkin, M.; Howick, J. What’s in Placebos: Who Knows? Analysis of Randomized, Controlled Trials. Ann. Intern. Med. 2010, 153, 532-536.